MCF7

(also called MCF-7) human caucasian mammary gland adenocarcinoma

Cell Type:
Mammary Epith.
Tissue Origin:
breast
Species:
human
Research Area:
Cancer Research/Cell Biology
Cell Characteristics:
Adherent

Recommended Media

RPMI-1640 medium was developed by Moore et al., at Roswell Park Memorial Institute, hence the acronym RPMI. The formulation is based on the RPMI-1630 series of media utilizing a bicarbonate buffering system and alterations in the amounts of amino acids and vitamins. RPMI-1640 medium has been used for the culture of human normal and neoplastic leukocytes. RPMI-1640 when properly supplemented, has demonstrated wide applicability for supporting growth of many types of cell cultures, including fresh human lymphocytes in the 72-hour phytohemagglutinin (PHA) stimulation assay.

There are a variety of formulations:
12-702         - with L-glutamine
BE12-702/U1 - with UltraGlutamineI
BE15-702D    - [powder] with L-glutamine
12-167          - without L-glutamine
12-115          - with L-glutamine and 25 mM HEPES buffer
BE12-115/U1 - with UltraGlutamineI and 25 mM HEPES buffer
04-525          - with L-glutamine and 165 nM MOPS (used for some mycological assays)
09-774          - with L-glutamine, 25 mM HEPES buffer 100 units/ml penicillin, 50 ug/ml streptomycin
12-918          - without L-glutamine or phenol red
BE12-752       - with L-glutamine, without D-glucose

Storage = 2ºC to 8ºC 
  (versions without L-glutamine and those with UltraGlutamine can be stored at 15ºC to 30ºC)

HL-1™ is a Serum-free culture medium containing less than 30 µg protein per ml. Components of HL-1 include known amounts of insulin, a variety of saturated and unsaturated fatty acids and proprietary stabilizing bovine proteins. It contains no bovine serum albumin and does not contain L-glutamine.
HL-1™ will support the serum-free growth of various hybridomas and certain other differentiated cells of lymphoid origin. 

Storage = 2°C to 8°C

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
SE

EN-130

4e5 78.2% ±1 52-66% Plasmid (general) 0.4 µg 20 µl 4D X-Unit
SE

EN-130

2e6 78.4% ±5 52-66% Plasmid (general) 2 µg 100 µl 4D X-Unit
V P-020 2e6 71% ±4 60% Plasmid (general) 2 µg 100 µl I/II/2b
SE 96-EN-130 4e5 72% ±3 59% ±7 Plasmid (general) 0.4 µg 20 µl Shuttle

Citations (31)

Categories:
Primary Cells and Media, Classical Media and Reagents, Serum-free and Speciality Media 
Authors:
Carpenter PM, Sivadas P, Hua SS, Xiao C, Gutierrez AB, Ngo T, Gershon PD 
In:
Cancer Medicine (2017) 6(1): 220-234 
Categories:
Classical Media and Reagents, Serum-free and Speciality Media 
Authors:
Ray A, Vasudevan S, Sengupta S 
In:
PLoS ONE (2015) 10(9): e0137614 
Categories:
Classical Media and Reagents, Serum-free and Speciality Media 
Authors:
Ahmadipour F, Noordin MI, Mohan S, Arya A, Paydar M, Looi CY, Keong YS, Siyamak EN, Fani S, Firoozi M, Yong CL1, Sukari MA, Kamalidehghan B 
In:
Other (2015) 9: 1193-208 
Categories:
Classical Media and Reagents, Serum-free and Speciality Media 
Authors:
Baldari S, Ubertini V, Garufi A, D\\\'Orazi G, Bossi G 
In:
Cell Death Dis. (2015) 6: e1621 
Categories:
 
Authors:
Pickholtz I, Saadyan S, Keshet GI, Wang VS, Cohen R, Bouwman P, Jonkers J, Byers SW6, Papa MZ, Yarden RI. 
In:
OncoTarget (2014) 2(23): 11827-46 
Categories:
Transfection 
Authors:
Duda K, Lonowski LA, Kofoed-Nielsen M, Ibarra A, Delay CM, Kang Q, Yang Z, Pruett-Miller SM, Bennett EP3, Wandall HH, Davis GD, Hansen SH, Frödin M. 
In:
Nucleic Acids Res (2014) 42: 1-16 
Categories:
Transfection 
Authors:
Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM 
In:
Mol Endocrinol (2008) 22(8): 1781-96 
Categories:
Transfection 
Authors:
Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H 
In:
Cancer Res (2008) 68(13): 5004-8 
Categories:
Transfection 
Authors:
Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK 
In:
J Biol Chem (2008) epub: online 
Categories:
Transfection 
Authors:
Hollingshead BD, Beischlag TV, Dinatale BC, Ramadoss P, Perdew GH 
In:
Cancer Res (2008) 68(10): 3609-17 
Categories:
Transfection 
Authors:
Bicaku E, Marchion DC, Schmitt ML, Münster PN 
In:
Cancer Res (2008) 68(5): 1513-9 
Categories:
Transfection 
Authors:
Johann AM, Weigert A, Eberhardt W, Kuhn AM, Barra V, von Knethen A, Pfeilschifter JM, Brüne B 
In:
J Immunol (2008) 180(2): 1239-48 
Categories:
Transfection 
Authors:
Com E, Lagadec C, Page A, El Yazidi-Belkoura I, Slomianny C, Spencer A, Hammache D, Rudkin BB, Hondermarck H 
In:
Mol Cell Proteomics (2007) 6(11): 1842-1854 
Categories:
Transfection 
Authors:
Weigert A, Tzieply N, von Knethen A, Johann AM, Schmidt H, Geisslinger G, Brüne B 
In:
Mol Biol Cell (2007) 18(10): 3810-9 
Categories:
Transfection 
Authors:
Hayashi T, Okabe T, Nasu-Nishimura Y, Sakaue F, Ohwada S, Matsuura K, Akiyama T, Nakamura T 
In:
Genes Cells (2007) 12(8): 929-39 
Categories:
Transfection 
Authors:
Trauernicht AM, Kim SJ, Kim NH, Boyer TG 
In:
Mol Endocrinol (2007) 21(7): 1526-36 
Categories:
Transfection 
Authors:
Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, Bouton AH 
In:
Cancer Res (2007) 67(13): 6174-82 
Categories:
Transfection 
Authors:
McGowan PM, Ryan BM, Hill AD, McDermott E, O'higgins N, Duffy MJ 
In:
Clin Cancer Res (2007) epub: online 
Categories:
Transfection 
Authors:
Park S, Rath O, Beach S, Xiang X, Kelly SM, Luo Z, Kolch W, Yeung KC 
In:
FEBS Lett (2006) 580(27): 6405-12 
Categories:
Transfection 
Authors:
Mitsui Y, Mochizuki S, Kodama T, Shimoda M, Ohtsuka T, Shiomi T, Chijiiwa M, Ikeda T, Kitajima M, Okada Y 
In:
Cancer Res (2006) 66(20): 9913-20 
Categories:
Transfection 
Authors:
Weiske J, Huber O 
In:
J Biol Chem (2006) 281(37): 27356-66 
Categories:
Transfection 
Authors:
von Kriegsheim A, Pitt A, Grindlay GJ, Kolch W, Dhillon AS 
In:
Nat Cell Biol (2006) 8(9): 1011-6 
Categories:
Transfection 
Authors:
Bushell M, Stoneley M, Kong YW, Hamilton TL, Spriggs KA, Dobbyn HC, Qin X, Sarnow P, Willis AE 
In:
Mol Cell (2006) 23(3): 401-12 
Categories:
Transfection 
Authors:
Enari M, Ohmori K, Kitabayashi I, Taya Y 
In:
Genes Dev (2006) 20(9): 1087-99 
Categories:
Transfection 
Authors:
Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G 
In:
J Natl Cancer Inst (2006) 98(10): 671-80 
Categories:
Transfection 
Authors:
Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G 
In:
Cancer Cell (2006) 9(4): 261-72 
Categories:
Transfection 
Authors:
Ding Y, Lee JF, Lu H, Lee MH, Yan DH 
In:
Mol Cell Biol (2006) 26(5): 1979-96 
Categories:
Transfection 
Authors:
Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ and Kolch W 
In:
Clin Cancer Res (2005) 11(20): 7392-7397 
Categories:
Transfection 
Authors:
Roy M, Li Z and Sacks DB 
In:
Mol Cell Biol (2005) 25(18): 7940-7952 
Categories:
Transfection 
Authors:
Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M and Sif S 
In:
Mol Cell Biol (2005) 25(18): 7953-7965 
Categories:
Transfection 
Authors:
Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K and Emi M 
In:
Endocr Relat Cancer (2005) 12(1): 65-73 
+ Show All